8 results on '"Ozdemir, Feyyaz"'
Number of results to display per page
Search Results
2. Turkish National Colon Cancer Registry
- Author
-
Benekli, Mustafa, Dumanli, Esra, Kilickap, Saadettin, Uncu, Dogan, Aliustaoglu, Mehmet, Cicin, Irfan, Gumus, Mahmut, Ozkan, Metin, Kocer, Murat, Karaoglu, Aziz, Dane, Faysal, Isikdogan, Abdurrahman, Elkiran, Tamer, Yalcin, Bulent, Uysal, Mukremin, Oksuzoglu, Berna, Boruban, Melih Cem, Ulas, Arife, Abali, Huseyin, Buyukberber, Suleyman, Tekin, Salim Basol, Avci, Nilufer, Sevinc, Alper, Ozdemir, Feyyaz, Ruchan Uslu, Turna, Hande, Ozturk, Banu, Kara, Oguz, and Kaya, Ali Osman
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Turkish ,Incidence (epidemiology) ,Advanced stage ,Cancer ,medicine.disease ,language.human_language ,Oncology ,Internal medicine ,medicine ,language ,T-stage ,Adenocarcinoma ,business ,Pathological - Abstract
e12646 Background: Colorectal cancers (CRC) have become the 3rd most common cancer in Turkey with increasing incidence over the years. Studies investigating the clinical and biologic features of CRC Turkey are small retrospective case series providing limited information. We initiated a Turkish National CRC Registry program in October 2012 to define clinical and pathological variables of CRC. Methods: Pts presenting to medical oncology clinics were prospectively registered in 28 centers nationwide. Pt demographics and clinicopathological characteristics were recorded. Results: 6143 pts (mean age 58.2±12.3) were analyzed (57% males). Mean ages of males were higher (59 vs 57 yrs, p = 0.001). Adenocarcinoma was the most common histology (97.8%). Initial stages at diagnosis: I (5.4%), II (29.6%), III (33.8%) and IV (20.2%), unknown (9.8%). Pts from Eastern Turkey were younger (56 vs 59, p < 0.001) with a more advanced stage (metastatic pts, 26.5% vs 18.4%). T stage was unknown in 22%, and T3 (46%) and T4 (20%...
- Published
- 2015
3. Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry
- Author
-
Kilickap, Saadettin, Altundag, Kadri, Dumanli, Esra, Gumus, Mahmut, Ruchan Uslu, Ozyilkan, Ozgur, Yalcin, Bulent, Kara, Oguz, Dogu, Gamze Gokoz, Ozturk, Banu, Kaya, Ali Osman, Aliustaoglu, Mehmet, Uncu, Dogan, Ozdemir, Feyyaz, Cicin, Irfan, Ozkan, Metin, Kocer, Murat, Turna, Hande, Buyukberber, Suleyman, Benekli, Mustafa, Coskun, Ugur, Karaoglu, Aziz, Tekin, Salim Basol, Dane, Faysal, Avci, Nilufer, Ulas, Arife, Oksuzoglu, Berna, Sevinc, Alper, Boruban, Melih Cem, and Çukurova Üniversitesi
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Turkish ,education ,Cancer ,medicine.disease ,language.human_language ,Breast cancer ,Internal medicine ,language ,Medicine ,Presentation (obstetrics) ,business - Abstract
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, IL WOS: 000358036902450 … Amer Soc Clin Oncol
- Published
- 2015
4. Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry
- Author
-
Benekli, Mustafa, Altundag, Kadri, Dumanli, Esra, Isikdogan, Abdurrahman, Karaoglu, Aziz, Tekin, Salim Basol, Oksuzoglu, Berna, Kocer, Murat, Sevinc, Alper, Boruban, Melih Cem, Turna, Hande, Ruchan Uslu, Ozyilkan, Ozgur, Yalcin, Bulent, Coskun, Ugur, Kilickap, Saadettin, Dogu, Gamze Gokoz, Ozturk, Banu, Gumus, Mahmut, Buyukberber, Suleyman, Uncu, Dogan, Kara, Oguz, Aliustaoglu, Mehmet, Ozkan, Metin, Cicin, Irfan, Elkiran, E. Tamer, Dane, Faysal, Avci, Nilufer, Ulas, Arife, Ozdemir, Feyyaz, and Kaya, Ali Osman
- Subjects
Cancer Research ,Oncology - Published
- 2015
5. Turkish National Breast Cancer Registry
- Author
-
Altundag, Kadri, Dumanli, Esra, Aliustaoglu, Mehmet, Uncu, Dogan, Ozkan, Metin, Cicin, Irfan, Coskun, Ugur, Elkiran, Tamer, Kocer, Murat, Isikdogan, Abdurrahman, Karaoglu, Aziz, Tekin, Salim Basol, Avci, Nilufer, Ulas, Arife, Oksuzoglu, Berna, Ozdemir, Feyyaz, Kilickap, Saadettin, Gumus, Mahmut, Buyukberber, Suleyman, Benekli, Mustafa, Dane, Faysal, Sevinc, Alper, Boruban, Melih Cem, Turna, Hande, Ruchan Uslu, Ozyilkan, Ozgur, Yalcin, Bulent, Kara, Oguz, Dogu, Gamze Gokoz, Ozturk, Banu, and Kaya, Ali Osman
- Subjects
Gynecology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Turkish ,Cancer ,medicine.disease ,humanities ,language.human_language ,Breast cancer ,Oncology ,Family medicine ,Epidemiology ,language ,Medicine ,business - Abstract
e12654 Background: Breast cancer (BC) is the most common cancer in women in Turkey. Studies investigating BC epidemiology in Turkey are retrospective case series providing limited information. We d...
- Published
- 2015
6. Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry
- Author
-
Coskun, Ugur, Altundag, Kadri, Aliustaoglu, Mehmet, Uncu, Dogan, Ozkan, Metin, Cicin, Irfan, Ciltas, Aydin, Elkiran, Tamer, Kocer, Murat, Isikdogan, Abdurrahman, Karaoglu, Aziz, Tekin, Salim Basol, Avci, Nilufer, Ulas, Arife, Oksuzoglu, Berna, Ozdemir, Feyyaz, Dumanli, Esra, Sevinc, Alper, Kilickap, Saadettin, Benekli, Mustafa, Ruchan Uslu, Ozyilkan, Ozgur, Yalcin, Bulent, Boruban, Melih Cem, Dane, Faysal, Kara, Oguz, Dogu, Gamze Gokoz, Ozturk, Banu, Kaya, Ali Osman, Gumus, Mahmut, and Turna, Hande
- Subjects
Oncology ,Gynecology ,Cancer Research ,medicine.medical_specialty ,Poor prognosis ,business.industry ,Turkish ,medicine.disease ,Obesity ,language.human_language ,Breast cancer ,Internal medicine ,medicine ,language ,business ,Pathological - Abstract
e12657 Background: Obesity is independently associated with breast cancer (BC) recurrence and poor prognosis despite therapy. However there is no data available about the effect of obesity on the n...
7. Turkish National Gastric Cancer Registry
- Author
-
Buyukberber, Suleyman, Dumanli, Esra, Uncu, Dogan, Ozkan, Metin, Ruchan Uslu, Dogu, Gamze Gokoz, Kara, Oguz, Abali, Huseyin, Turna, Hande, Ozturk, Banu, Sevinc, Alper, Uysal, Mukremin, Yalcin, Bulent, Dane, Faysal, Aliustaoglu, Mehmet, Cicin, Irfan, Tekin, Salim Basol, Gumus, Mahmut, Kilickap, Saadettin, Benekli, Mustafa, Kocer, Murat, Oksuzoglu, Berna, Isikdogan, Abdurrahman, Ozdemir, Feyyaz, Elkiran, E. Tamer, Karaoglu, Aziz, Boruban, Cem, Avci, Nilufer, and Çukurova Üniversitesi
- Subjects
Oncology ,Gynecology ,Cancer Research ,medicine.medical_specialty ,Turkish ,business.industry ,Incidence (epidemiology) ,digestive, oral, and skin physiology ,education ,Cancer ,Malignancy ,medicine.disease ,digestive system diseases ,language.human_language ,Cancer registry ,Internal medicine ,medicine ,language ,business - Abstract
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, IL WOS: 000358036902440 … Amer Soc Clin Oncol
8. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
- Author
-
Feyyaz Ozdemir, Deniz Yuce, Mehmet Ali Ustaoglu, Bulent Karabulut, Hakan Akbulut, Metin Ozkan, Guzin Demirag, Mutlu Hayran, Faysal Dane, Turkkan Evrensel, Tugba Yavuzsen, Berna Oksuzoglu, Abdurrahman Isikdogan, Alper Sevinc, Nuriye Ozdemir, Saadettin Kilickap, Suayib Yalcin, Hande Turna, Faruk Aykan, Hasan Şenol Coşkun, Yalcin, Suayib, Dane, Faysal, Oksuzoglu, Berna, Ozdemir, Nuriye Yildirim, Isikdogan, Abdurrahman, Ozkan, Metin, Demirag, Guzin Gonullu, Coskun, Hasan Senol, Karabulut, Bulent, Evrensel, Turkkan, Ustaoglu, Mehmet Ali, Ozdemir, Feyyaz, Turna, Hande, Yavuzsen, Tugba, Aykan, Faruk, Sevinc, Alper, Akbulut, Hakan, Yuce, Deniz, Hayran, Mutlu, Kilickap, Saadettin, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalı, Işıkdoğan, Abdurrahman, OMÜ, and Ege Üniversitesi
- Subjects
Oncology ,Adult ,Male ,Quality of life ,Cancer Research ,medicine.medical_specialty ,Combination therapy ,Paclitaxel ,Phases of clinical research ,Adenocarcinoma ,Nab-paclitaxel ,lcsh:RC254-282 ,Deoxycytidine ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Pancreatic cancer ,Albumins ,Genetics ,medicine ,Humans ,030212 general & internal medicine ,Neoplasm Metastasis ,Aged ,Neoplasm Staging ,business.industry ,Metastatic Pancreatic Adenocarcinoma ,Middle Aged ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Survival Analysis ,Gemcitabine ,CANCER ,Pancreatic Neoplasms ,FOLFIRINOX ,030220 oncology & carcinogenesis ,Toxicity ,Metastatic ,Drug Therapy, Combination ,Female ,TRIAL ,business ,medicine.drug ,Research Article - Abstract
BackgroundCombination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in advanced pancreatic adenocarcinoma is unknown.MethodsA total of 125 patients were randomized to combination therapy (1000mg/m2 gemcitabine +125mg/m2 nab-paclitaxel) and single-agent gemcitabine (1000mg/m2) arms to take treatment weekly for 7 of 8weeks, and following 3 of 4weeks, until progression or severe toxicity. Primary endpoints were three-months of definitive deterioration free percent of patients, and QoL.ResultsOverall QoL analyses showed that 34 and 58.3% of cases in gemcitabine and gemcitabine+nab-P arms had no deterioration in 3rd month QoL scores (p=0.018). These proportions were 27.3 and 36.6% in 6(th) month assessments, respectively (p=0.357). Median overall survivals in combination and single-agent arms were 9.92months and 5.95months, respectively (HR: 0.64, 95% CI: 0.42-0.86, p=0.038). Median progression free survivals in these treatment arms were 6.28 and 3.22months, respectively (HR: 0.58, 95% CI: 0.39-0.87, p=0.008). Median time-to-deterioration were 5.36 vs 3.68months, and objective response rates were 37.1% vs 23.7% (p=0.009), respectively in combination and single-agent arms.ConclusionsCombination therapy with gemcitabine + nab-paclitaxel had better overall and progression-free survival than gemcitabine alone. Also, combination therapy showed increased response rate without toxicity or deteriorated QoL. Combination treatment with gemcitabine and nab-paclitaxel may provide significant benefit for advanced pancreatic cancer.Trial registrationThis study has been registered in ClinicalTrials.gov as NCT03807999 on January 8, 2019 (retrospectively registered)., Celgene [aaaa] Funding Source: Medline; onkoloji arastirmalari dernegi [aaa] Funding Source: Medline; hacettepe onkoloji dernegi [wwww] Funding Source: Medline; Turk Kanser Arastirma ve Savas Kurumu Dernegi [awe] Funding Source: Medline; Turk Tibbi Onkoloji Dernegi (TR) [wwww] Funding Source: Medline
- Published
- 2020
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.